Olmutinib

Base Information

Chemical Name:Olmutinib
CAS No.:1353550-13-6
Molecular Formula:C26H26N6O2S
Molecular Weight:486.597
Hs Code.:
Mol file:1353550-13-6.mol

Synonyms:HM-71224;Olmutinib;Olmutinib, HM71224;N-(3-(2-(4-(4-methylpiperazin-1-yl)phenylamino)thieno[3,2-d]pyrimidin-4-yloxy)phenyl)acrylamide dihydrochloride monohydrate;N-(3-(2-(4-(4-methylpiperazin-1-yl)phenylamino)thieno[3,2-d]pyrimidin-4-yloxy)phenyl)acrylamide;N-[3-[[2-[[4-(4-Methyl-1-piperazinyl)phenyl]amino]thieno[3,2-d]pyrimidin-4-yl]oxy]phenyl]-2-propenamide;HM71224, Olmutinib;Olmutinib (HM61713, BI 1482694)

Suppliers and Price of Olmutinib

Supply Marketing:

Business phase:: The product has achieved commercial mass production^*data from LookChem market partment

Manufacturers and distributors:

Manufacture/Brand
Chemicals and raw materials
Packaging
price

TRC
Olmutinib
25mg
$ 360.00

Medical Isotopes, Inc.
Olmutinib
200 mg
$ 490.00

DC Chemicals
HM-61713(BI-1482694) >98%
100 mg
$ 380.00

Crysdot
Olmutinib 98+%
100mg
$ 539.00

Crysdot
Olmutinib 98+%
50mg
$ 393.00

Crysdot
Olmutinib 98+%
250mg
$ 850.00

ChemScene
Olmutinib 99.99%
200mg
$ 540.00

ChemScene
Olmutinib 99.99%
10mg
$ 96.00

ChemScene
Olmutinib 99.99%
5mg
$ 60.00

ChemScene
Olmutinib 99.99%
100mg
$ 336.00

Total 27 raw suppliers

Chemical Property of Olmutinib

Chemical Property:

PKA:12.87±0.70(Predicted)
PSA：110.86000
Density:1.336±0.06 g/cm3(Predicted)
LogP:5.25240
Solubility.:insoluble in H2O; ≥9.11 mg/mL in EtOH with ultrasonic; ≥96.6 mg/mL in DMSO

Purity/Quality:

99%, ^*data from raw suppliers

Olmutinib ^*data from reagent suppliers

Safty Information:

Pictogram(s):
Hazard Codes:

MSDS Files:: SDS file from LookChem

Useful:

Description Olmutinib, codeveloped by Boehringer Ingelheim and Hanmi Pharmaceutical Co., was approved by the Korean Ministry of Food and Drug Safety (MFDS) for treatment of locally advanced or metastatic EGFR T790 M mutation-positive non-small cell lung cancer (NSCLC). Olmutinib serves as a third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI), which is being used as an oral therapy for patients who have previously been treated with an alternate EGFR TKI. Firstand second-generation EGFR TKIs, which bind reversibly and irreversibly to the TK domain, respectively, are both generally effective at onset of treatment but result in development of resistance within the first year of treatment. Thirdgeneration EGFR TKIs such as olmutinib have demonstrated the ability to covalently bind to the kinase domain of EGFR while sparing wild-type EGFR, leading to irreversible inhibition of both EGFR mutations and the T790 M mutation, which is linked to EGFR TKI resistance. HM61713 is a third generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that inhibits both EGFR activating and T790M resistance mutations, while sparing wild-type EGFR. It has been investigated in Phase II clinical trials in patients with EGFR T790M mutation-positive non-small cell lung cancer (NSCLC), who developed resistance to earlier generations of EGFR tyrosine kinase inhibitor therapy.
Uses Olmutinib is an epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) against non-small cell lung cancer (NSCLC).

Technology Process of Olmutinib

There total 13 articles about Olmutinib which guide to synthetic route it. The literature collected by LookChem mainly comes from the sharing of users and the free literature resources found by Internet computing technology. We keep the original model of the professional version of literature to make it easier and faster for users to retrieve and use. At the same time, we analyze and calculate the most feasible synthesis route with the highest yield for your reference as below:

synthetic route:

Reference yield: 84.0%